Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Research & Development (2016 - 2025)

Adma Biologics (ADMA) has disclosed Research & Development for 13 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 252.17% year-over-year to $1.4 million, compared with a TTM value of $4.8 million through Dec 2025, up 162.66%, and an annual FY2025 reading of $4.8 million, up 162.66% over the prior year.
  • Research & Development was $1.4 million for Q4 2025 at Adma Biologics, down from $1.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $1.5 million in Q3 2025 and bottomed at $391000.0 in Q4 2024.
  • Average Research & Development over 5 years is $856750.0, with a median of $840500.0 recorded in 2023.
  • The sharpest move saw Research & Development crashed 60.09% in 2024, then skyrocketed 270.87% in 2025.
  • Year by year, Research & Development stood at $728928.0 in 2021, then soared by 47.42% to $1.1 million in 2022, then plummeted by 58.49% to $446000.0 in 2023, then dropped by 12.33% to $391000.0 in 2024, then skyrocketed by 252.17% to $1.4 million in 2025.
  • Business Quant data shows Research & Development for ADMA at $1.4 million in Q4 2025, $1.5 million in Q3 2025, and $1.0 million in Q2 2025.